AGORACOM Small Cap 60: The XPhyto Psychedelics Program & What Creates Success



XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF) is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids.

Commercialization of rapid COVID-19 PCR test
Rapid, low-cost, point-of-care infectious disease screening tools for Covid 19
Can provide results within 25 minutes
Test Trials Underway in Germany & Israel
European Sales Expected in 2021
Psychedelic API production, drug formulation and clinical integration
Production of active pharmaceutical ingredients from psychedelics and cannabinoid treat mental health issues such as depression, anxiety, addiction, anorexia and post traumatic stress disorder
2 Psychedelic Agreements signed
Drug Formulations and Delivery
Clinical validation of Oral Thin Film Drug Delivery Programs ongoing

The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.

Source: Youtube